Myrtelle

Myrtelle Myrtelle Inc. When not broken down by oligodendrocytes, NAA accumulates in the brain and disrupts the normal bioenergetics, myelin production, and brain health.

is a gene therapy company focused on providing hope and progress by developing transformative treatments for neurodegenerative diseases that affect patients who have few, if any, treatment options. Our lead program is a novel investigational gene therapy treatment for Canavan disease (CD), a fatal genetic brain disorder in which mutations in the ASPA gene prevent the normal expression of Aspartoac

ylase, a critical enzyme produced in oligodendrocyte cells that breaks down the neurochemical N-Acetylaspartic Acid (NAA). CD patients are affected at birth but may appear normal until several months, when symptoms begin to develop. Poor head control, abnormally large head size, eye tracking difficulty, excessive irritability, severely diminished muscle tone, and delays in reaching motor milestones such as rolling, sitting, and walking are typical. As the disease progresses, seizures, spasticity, difficulties in swallowing, and overall muscle deterioration emerge, with most affected children developing life-threatening complications by ten years of age. Currently, there is no cure for CD and only palliative treatments are available. Myrtelle’s social media channels are places for community members to connect and learn about Myrtelle’s initiatives. Discussion of medical and health topics should never be construed as medical advice. Contact a healthcare professional in your area for personal medical advice. Myrtelle does not represent that the information on our social media channels is accurate, complete, reliable, useful, timely, or current and Myrtelle does not undertake an obligation to update any such information. Myrtelle does not endorse any opinions or statements expressed by others on our social media channels. Myrtelle does not expressly endorse opinions or statements expressed by individuals, businesses, or channels we may ‘follow’, ‘like’, or ‘share’. At times, Myrtelle may link to external websites. Myrtelle is not responsible for the content or policies of these websites. Content submitted to our social media channels is public and will not place Myrtelle under any obligation to you.

Early intervention changes everything. We're fighting to get Canavan disease added to newborn screening panels so famili...
06/02/2026

Early intervention changes everything. We're fighting to get Canavan disease added to newborn screening panels so families can access life-altering gene therapies the moment the treatment window opens.
Read more: www.myrtellegtx.com

At Myrtelle, we know that every number behind a clinical trial has a name behind it. Learn more about the five month old...
05/19/2026

At Myrtelle, we know that every number behind a clinical trial has a name behind it. Learn more about the five month old who became one of the youngest in the world to receive our gene therapy and within weeks was observed with increased alertness and laughter.

Read more: https://bit.ly/3Rg7dPU

By leveraging FDA START and RMAT designations, Myrtelle is accelerating the development of MYR-101 to deliver a life-cha...
05/05/2026

By leveraging FDA START and RMAT designations, Myrtelle is accelerating the development of MYR-101 to deliver a life-changing treatment promise to families living with Canavan disease.

Read more: myrtellegtx.com/canavan-disease

An Irish infant has become one of the first in the world to receive a pioneering experimental gene therapy in the U.S., ...
05/01/2026

An Irish infant has become one of the first in the world to receive a pioneering experimental gene therapy in the U.S., offering new hope in the fight against the neurodegenerative Canavan disease.

Read original article:
https://bit.ly/4mXnkNS

A meaningful moment for the Canavan disease community. Thank you The Irish Times and  for featuring Myrtelle’s gene ther...
04/30/2026

A meaningful moment for the Canavan disease community. Thank you The Irish Times and for featuring Myrtelle’s gene therapy program - underscoring both scientific progress and the urgency behind it for the children and families we serve, as well as, the potential impact for other white matter diseases.

Scientists hope trial will lead to treatment for rare and fatal Canavan disease

Establishing universal newborn screening for Canavan disease is the next critical frontier in protecting children’s futu...
04/29/2026

Establishing universal newborn screening for Canavan disease is the next critical frontier in protecting children’s futures through early, life-changing gene therapy intervention.

Read more: https://bit.ly/3QA5nJj

The FDA's recent approval of Otarmeni for OTOF-related deafness marks a historic milestone in genetic medicine that pave...
04/28/2026

The FDA's recent approval of Otarmeni for OTOF-related deafness marks a historic milestone in genetic medicine that paves the way for life-changing breakthroughs in neurodegenerative conditions like Canavan disease.

Read more about our mission to treat Canavan disease: myrtellegtx.com/canavan-disease

We’re racing against time to transform the urgency of missed milestones into life-changing action for children with Cana...
04/21/2026

We’re racing against time to transform the urgency of missed milestones into life-changing action for children with Canavan disease.

Read more: https://myrtellegtx.com

Address

Wakefield, MA
01880

Alerts

Be the first to know and let us send you an email when Myrtelle posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share